The ROE as of October 2024 (TTM) for Adaptimmune Therapeutics plc (ADAP) is -117.47%

According to Adaptimmune Therapeutics plc’s latest financial reports and current stock price. The company's current ROE is -117.47%. This represents a change of 56.19% compared to the average of -75.21% of the last 4 quarters.

Adaptimmune Therapeutics plc (ADAP) Historical ROE (quarterly & annually)

How has ADAP ROE performed in the past?

The mean historical ROE of Adaptimmune Therapeutics plc over the last ten years is -136.89%. The current -117.47% ROE has changed -14.19% with respect to the historical average. Over the past ten years (40 quarters), ADAP's ROE was at its highest in in the June 2024 quarter at 72.21%. The ROE was at its lowest in in the March 2015 quarter at -365.03%.

Adaptimmune Therapeutics plc (ADAP) ROE by Quarter and Year

Discovering the peaks and valleys of Adaptimmune Therapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Adaptimmune Therapeutics plc (ADAP) Average ROE

How has ADAP ROE performed in the past?

The current ROE of Adaptimmune Therapeutics plc (ADAP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Adaptimmune Therapeutics plc (ADAP) ROE vs. Peers

How is ADAP’s ROE compared to its peers?

Adaptimmune Therapeutics plc’s ROE is greater than Stoke Therapeutics, Inc. (-57.89%), greater than Homology Medicines, Inc. (-100.91%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Harpoon Therapeutics, Inc. (-904.27%), greater than Mereo BioPharma Group plc (-63.39%), greater than Pieris Pharmaceuticals, Inc. (-97.28%), greater than PDS Biotechnology Corporation (-137.06%), greater than Leap Therapeutics, Inc. (-98.01%), greater than Affimed N.V. (-155.57%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), greater than Aptose Biosciences Inc. (-5693.38%), greater than Nkarta, Inc. (-28.83%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Adicet Bio, Inc. (-63.95%), less than MiNK Therapeutics, Inc. (99.78%), greater than ImmunoGen, Inc. (-21.97%), greater than Sangamo Therapeutics, Inc. (-334.92%),

Build a custom stock screener for Adaptimmune Therapeutics plc (ADAP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adaptimmune Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Adaptimmune Therapeutics plc (ADAP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Adaptimmune Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.